Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
← catalyst calendarSponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
198actual
Sites
15
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-18 | actual | When the study began enrolling |
| Primary completion | 2026-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Essential Hypertension
Interventions
- Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg — also filed as Truset 40/5/12.5mg
- Drug: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg — also filed as Twynsta 40/5 mg, Dichlozid 25 mg
Primary outcome
what the primary-completion date above is the date OFMean Systolic Blood Pressure (MSBP) in nighttime
measured Week 8
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed